Get the Stockscreener App
5.055
3.52%
-0.195
Aldeyra Therapeutics Inc stock is traded at $5.055, with a volume of 1.46M.
It is down -3.52% in the last 24 hours and up +3.16% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$5.25
Open:
$5.27
24h Volume:
1.46M
Relative Volume:
1.54
Market Cap:
$304.72M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-6.74
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
+10.35%
1M Performance:
+3.16%
6M Performance:
+59.78%
1Y Performance:
+3.79%
1-Day Range:
$5.00
$5.675
1-Week Range:
$3.94
$5.675
52-Week Range:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.065 | 315.85M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.73 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.51 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.14 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.82 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.07 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Aldeyra drops as FDA delays review of marketing application for lead drug - MSN
Why is Aldeyra Therapeutics stock surging after FDA delayed its dry eye drug decision? - MSN
Aldeyra Therapeutics Target of Unusually Large Options Trading (NASDAQ:ALDX) - MarketBeat
Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside - TipRanks
Aldeyra Therapeutics (NASDAQ: ALDX) updates on FDA review of reproxalap - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision? - Stocktwits
ALDX: FDA extends reproxalap NDA review by 90 days after requiring field trial CSR submission - TradingView — Track All Markets
Aldeyra Therapeutics (ALDX) Faces FDA Review Delay for Reproxala - GuruFocus
Why Is Aldeyra Therapeutics Stock Falling Tuesday?Aldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Aldeyra stock drops on FDA delay for lead drug (ALDX:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Aldeyra Therapeutics Faces FDA PDUFA Date Extension - TipRanks
Aldeyra Says FDA Extends Action Date for Potential Dry Eye Disease Treatment; Shares Down Pre-Bell - marketscreener.com
Aldeyra Therapeutics Announces PDUFA Extension for Reproxalap NDA - TradingView — Track All Markets
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Aldeyra (ALDX) Receives Extended FDA Action Date for Reproxalap NDA - GuruFocus
Aldeyra (Nasdaq: ALDX) PDUFA review of reproxalap dry eye NDA extended to Mar. 2026 - Stock Titan
Aldeyra Therapeutics announces PDUFA extension of the new drug application of Reproxalap for the treatment of dry eye disease - marketscreener.com
683 Capital Management LLC Has $4.14 Million Stake in Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Adversity is less terrifying than hope: Aldeyra Therapeutics Inc (ALDX) - setenews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - 28/22 News
Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Aldeyra Therapeutics, Inc. $ALDX Shares Sold by Kennedy Capital Management LLC - MarketBeat
Winners Losers: Will Aldeyra Therapeutics Inc stock maintain momentum in 2025 - BỘ NỘI VỤ
It makes sense and dollars to buy Aldeyra Therapeutics Inc (ALDX) stock - setenews.com
Aldeyra Therapeutics Inc (137.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Aldeyra Therapeutics Inc. stock oversold or undervaluedCEO Change & Smart Allocation Stock Reports - Newser
Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Bull Run & Free Technical Confirmation Trade Alerts - moha.gov.vn
Can Aldeyra Therapeutics Inc. stock deliver surprise earnings beatChart Signals & Long-Term Capital Growth Strategies - moha.gov.vn
Will Aldeyra Therapeutics Inc. stock benefit from infrastructure spendingJuly 2025 Analyst Calls & Fast Entry and Exit Trade Plans - moha.gov.vn
Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet? - simplywall.st
Kennondale Capital Management LLC Sells 94,551 Shares of Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Why retail investors favor Aldeyra Therapeutics Inc. stock2025 Short Interest & Free Growth Oriented Trading Recommendations - newser.com
Aldeyra Therapeutics Inc Stock Analysis and ForecastContrarian Investment Ideas & Small Investment Trading Tips - earlytimes.in
The time has not yet come to remove your chips from the table: Aldeyra Therapeutics Inc (ALDX) - Setenews
Dry Eye Disease Market Size was ~USD 3.76 Billion in 2023 and expected to Grow by 2034, Analysed DelveInsight - Barchart.com
HC Wainwright Has Bullish Estimate for ALDX FY2025 Earnings - Defense World
What sentiment indicators say about Aldeyra Therapeutics Inc. stockJuly 2025 News Drivers & AI Based Buy/Sell Signal Reports - newser.com
Intraday pattern recognizer results for Aldeyra Therapeutics Inc.July 2025 Closing Moves & Daily Profit Maximizing Trade Tips - newser.com
Aldeyra Therapeutics Inc. stock daily chart insightsTrend Reversal & AI Forecast Swing Trade Picks - newser.com
Understanding Aldeyra Therapeutics Inc.’s price movement - newser.com
Live market analysis of Aldeyra Therapeutics Inc.CEO Change & Short-Term High Return Ideas - newser.com
How Aldeyra Therapeutics Inc. stock performs in weak economyGap Down & Weekly Market Pulse Alerts - newser.com
Why Aldeyra Therapeutics Inc. stock is in analyst buy zonePortfolio Update Summary & High Conviction Buy Zone Alerts - newser.com
Can a trend reversal in Aldeyra Therapeutics Inc. lead to recoveryPortfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
Applying Wyckoff theory to Aldeyra Therapeutics Inc. stock2025 Market Trends & Daily Growth Stock Investment Tips - newser.com
Brokers Offer Predictions for ALDX Q1 Earnings - Defense World
What candlestick patterns are forming on Aldeyra Therapeutics Inc.Market Growth Report & Risk Managed Trade Strategies - newser.com
Aldeyra Therapeutics Inc.’s volatility index tracking explainedMarket Performance Recap & Real-Time Volume Surge Alerts - newser.com
Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry EyeSlideshow (NASDAQ:ALDX) 2025-11-16 - Seeking Alpha
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):